{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-23-000088","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.989765+00:00","generated_at":"2026-06-12T04:04:29.699228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SI-BONE Q2 revenue $33.3M (+30% YoY); raises FY 2023 revenue guidance to $132-134M","bullets":["Record worldwide revenue $33.3M (+30% YoY); U.S. revenue $31.2M (+31% YoY).","Net loss improved to $11.2M ($0.30 diluted loss) from $18.5M ($0.54) in Q2 2022.","Adjusted EBITDA loss narrowed 59% to -$4.7M from -$11.5M.","FY 2023 revenue guidance raised to $132-134M (prior $128-131M), implying 24-26% growth.","Gross margin 81% vs 86% a year ago, impacted by product mix and higher depreciation."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-23-000088","json":"https://secwatch.observer/filing/0001459839-23-000088.json","markdown":"https://secwatch.observer/filing/0001459839-23-000088.md","text":"https://secwatch.observer/filing/0001459839-23-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/0001459839-23-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/sibn-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:04:29.699228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc1d13efdf62c49b03d0870fd589ae691ad6d710","claim":"SI-BONE, Inc. reported the quarter ended June 30, 2023 results: revenue $33.3 million, net income $11.2 million, or $0.30 per diluted share, EPS $0.30 per diluted share. Guidance raised.","evidence_excerpt":"musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2023. Recent Highlights • Record worldwide revenue of $33.3 million for the second quarter 2023, representing approximately 30% growth over the corresponding period in 2022 • Record U.S. revenue of $31.2 million for the second quarter 2023,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/0001459839-23-000088-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$33.3 million"},{"label":"Net income","value":"$11.2 million, or $0.30 per diluted share"},{"label":"EPS","value":"$0.30 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}